Comparative Pharmacology
Head-to-head clinical analysis: CORTAN versus HC 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTAN versus HC 4.
CORTAN vs HC #4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
HC #4 is a complex homeopathic preparation with no well-defined molecular mechanism; it is believed to act via hormesis or placebo effects.
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
Hydrocortisone 100-300 mg IV bolus, followed by 100-200 mg IV every 6 hours for 24-48 hours; then taper as clinically indicated.
None Documented
None Documented
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Terminal elimination half-life: 12 hours (range 10–14 hours). Extends to 24 hours in severe renal impairment (CrCl <30 mL/min); dose adjustment recommended.
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Renal excretion of unchanged drug: 95%; fecal/biliary: <5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid